InterAction

InterAction is a drug discovery company focused on the development of small molecule inhibitors of protein-protein interactions (PPIs). The company utilizes a proprietary platform that combines computational design with chemical synthesis to target challenging protein interfaces that were previously considered undruggable. By focusing on PPIs, InterAction aims to develop highly specific therapeutics for a range of diseases, including oncology and infectious diseases. The company's approach leverages structural biology and advanced screening techniques to identify and optimize novel chemical entities. InterAction is currently advancing several pre-clinical programs through its internal pipeline and collaborative efforts.